Drs. Andy Phillips (C4 Therapeutics) and Michael “Mick” Soth (MD Anderson IACS) will speak on Targeted Protein Degradation and Targeting Glutaminase Addition in Cancer: Development of a GLS1 Inhibitor, respectively.  Seating is limited to 70, so be sure and register early where you will also have the opportunity to include your questions for the interactive discussion session that will follow the presentations.